Stereotaxis this week announced it has forged a broad collaboration with Shanghai Microport EP Medtech to advance technology innovation and commercial adoption of electrophysiology robotics in China.
The agreement combines MicroPort EP’s commercial and product expertise in China’s electrophysiology market and Sterotaxis’s Robotic Magnetic Navigation technology. Through the collaboration, MicroPort EP will be the exclusive distributor of StereoTaxis’s Robotic Magnetic Navigation system for electrophysiology in China. MicroPort will also pursue regulatory approvals for Stereotaxis’s innovations including the Genesis RMN system and other magnetic ablation catheters.
Stereotaxis’s robotic systems will also be integrated with MicroPort EP’s Columbus mapping system through the agreement. Both companies will work to develop a family of cardiac ablation and diagnostic catheters.
“I am very excited by the promise of this …